Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 24,150 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe
BURLINGTON, Mass. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts for the second consecutive year. The rankings are based on the results from an annual employee survey conducted by The
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights
Company reported net ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) sales of $7.0 million in Q3 representing 84% growth over Q2 Strong progress in Commercial activities: 79% of target accounts have purchased, or received samples of, ZILRETTA and 64% of ordering
View HTML
Toggle Summary Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
BURLINGTON, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension).
View HTML
Toggle Summary Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018
BURLINGTON, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2018 financial results after the close of the U.S. financial markets on Wednesday, November 7, 2018 . Flexion’s management will host a conference call
View HTML
Toggle Summary Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting
Data presented at 2018 American College of Rheumatology (ACR) Annual Meeting show concurrent, bilateral administration of ZILRETTA appeared safe and well tolerated Systemic exposure to triamcinolone acetonide was 10-fold lower with ZILRETTA compared to traditional immediate-release TAcs Four out of
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,600 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology
Phase 2 data evaluating ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) in patients with Type 2 diabetes demonstrated lower blood glucose levels following ZILRETTA injection compared to TAcs injection Approximately 30% of patients with Type 2 diabetes also have
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 10,500 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference
BURLINGTON, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will present at the 13 th Annual Wells Fargo Securities Healthcare Conference taking place at the Westin Copley Place in Boston, Massachusetts .
View HTML